112 related articles for article (PubMed ID: 29790419)
1. RICTOR gene amplification is correlated with metastasis and therapeutic resistance in triple-negative breast cancer.
El Shamieh S; Saleh F; Moussa S; Kattan J; Farhat F
Pharmacogenomics; 2018 Jun; 19(9):757-760. PubMed ID: 29790419
[TBL] [Abstract][Full Text] [Related]
2. Rictor promotes tumor progression of rapamycin-insensitive triple-negative breast cancer cells.
Watanabe R; Miyata M; Oneyama C
Biochem Biophys Res Commun; 2020 Oct; 531(4):636-642. PubMed ID: 32819718
[TBL] [Abstract][Full Text] [Related]
3. PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.
Beck C; Rodriguez-Vargas JM; Boehler C; Robert I; Heyer V; Hanini N; Gauthier LR; Tissier A; Schreiber V; Elofsson M; Reina San Martin B; Dantzer F
Cell Death Differ; 2019 Sep; 26(9):1615-1630. PubMed ID: 30442946
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
5. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
6. Correlation between RICTOR overexpression and amplification in advanced solid tumors.
Bang H; Ahn S; Ji Kim E; Kim ST; Park HY; Lee J; Kim KM
Pathol Res Pract; 2020 Jan; 216(1):152734. PubMed ID: 31740232
[TBL] [Abstract][Full Text] [Related]
7. The role of RICTOR amplification in targeted therapy and drug resistance.
Zhao D; Jiang M; Zhang X; Hou H
Mol Med; 2020 Feb; 26(1):20. PubMed ID: 32041519
[TBL] [Abstract][Full Text] [Related]
8. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
9. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
Zhao ZM; Yost SE; Hutchinson KE; Li SM; Yuan YC; Noorbakhsh J; Liu Z; Warden C; Johnson RM; Wu X; Chuang JH; Yuan Y
BMC Cancer; 2019 Jan; 19(1):96. PubMed ID: 30665374
[TBL] [Abstract][Full Text] [Related]
10. RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.
Sakre N; Wildey G; Behtaj M; Kresak A; Yang M; Fu P; Dowlati A
Oncotarget; 2017 Jan; 8(4):5992-6002. PubMed ID: 27863413
[TBL] [Abstract][Full Text] [Related]
11. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer.
Niu J; Xue A; Chi Y; Xue J; Wang W; Zhao Z; Fan M; Yang CH; Shao ZM; Pfeffer LM; Wu J; Wu ZH
Oncogene; 2016 Mar; 35(10):1302-1313. PubMed ID: 26028030
[TBL] [Abstract][Full Text] [Related]
12. Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
Jouali F; Marchoudi N; Talbi S; Bilal B; El Khasmi M; Rhaissi H; Fekkak J
BMC Cancer; 2018 Sep; 18(1):900. PubMed ID: 30227836
[TBL] [Abstract][Full Text] [Related]
13. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
14. Novel RICTOR amplification harbouring entities: FISH validation of RICTOR amplification in tumour tissue after next-generation sequencing.
Sztankovics D; Krencz I; Moldvai D; Dankó T; Nagy Á; Nagy N; Bedics G; Rókusz A; Papp G; Tőkés AM; Pápay J; Sápi Z; Dezső K; Bödör C; Sebestyén A
Sci Rep; 2023 Nov; 13(1):19610. PubMed ID: 37949943
[TBL] [Abstract][Full Text] [Related]
15. PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
Wei W; Zou Y; Jiang Q; Zhou Z; Ding H; Yan L; Yang S
Int J Biol Markers; 2018 Jan; 33(1):102-108. PubMed ID: 28623645
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
Jovanović B; Mayer IA; Mayer EL; Abramson VG; Bardia A; Sanders ME; Kuba MG; Estrada MV; Beeler JS; Shaver TM; Johnson KC; Sanchez V; Rosenbluth JM; Dillon PM; Forero-Torres A; Chang JC; Meszoely IM; Grau AM; Lehmann BD; Shyr Y; Sheng Q; Chen SC; Arteaga CL; Pietenpol JA
Clin Cancer Res; 2017 Aug; 23(15):4035-4045. PubMed ID: 28270498
[No Abstract] [Full Text] [Related]
17. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
Balko JM; Schwarz LJ; Luo N; Estrada MV; Giltnane JM; Dávila-González D; Wang K; Sánchez V; Dean PT; Combs SE; Hicks D; Pinto JA; Landis MD; Doimi FD; Yelensky R; Miller VA; Stephens PJ; Rimm DL; Gómez H; Chang JC; Sanders ME; Cook RS; Arteaga CL
Sci Transl Med; 2016 Apr; 8(334):334ra53. PubMed ID: 27075627
[TBL] [Abstract][Full Text] [Related]
18. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
[TBL] [Abstract][Full Text] [Related]
19. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
[TBL] [Abstract][Full Text] [Related]
20. Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.
Lips EH; Michaut M; Hoogstraat M; Mulder L; Besselink NJ; Koudijs MJ; Cuppen E; Voest EE; Bernards R; Nederlof PM; Wesseling J; Rodenhuis S; Wessels LF;
Breast Cancer Res; 2015 Oct; 17(1):134. PubMed ID: 26433948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
